Sign In
Buy MYL
$15.86
+0 (+0%)
At Close: May 27, 2022
Mylan to Release Second Quarter 2020 Financial Results on Aug. 6, 2020
11:30am, Wednesday, 22'nd Jul 2020
Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its second quarter 2020 financial results on Thurs., Aug. 6, before the open of the U.S. financial markets.
MYL INVESTORS: August 25, 2020 Filing Deadline in Class Action - Contact Lieff Cabraser
01:00pm, Friday, 17'th Jul 2020
If you purchased the common stock of Mylan during the Class Period, you may move the Court for appointment as lead plaintiff by no later than August 25, 2020. A lead plaintiff is a representative par
4 Ways Biogen's Tecfidera Generic Battle Could Play Out For The Stock
09:55pm, Wednesday, 15'th Jul 2020
Biogen Inc (NASDAQ: BIIB) is caught in more than one legal wrangle with generic companies over patents related to its key multiple sclerosis drug Tecfidera, which was approved by the FDA in March 2013
MYL SHAREHOLDERS: August 25, 2020 Filing Deadline in Class Action – Contact Lieff Cabraser
01:00pm, Tuesday, 14'th Jul 2020
MYL SHAREHOLDERS: August 25, 2020 Filing Deadline in Class Action – Contact Lieff Cabraser
Pfizer Surges On Fast Track For Coronavirus Vaccine — But Is PFE Stock A Buy?
02:30pm, Monday, 13'th Jul 2020
Pfizer stock is forming a cup-with-handle base as the Street intently watches its coronavirus vaccine efforts with BioNTech. But is the pharmaceutical company's stock a buy right now?
Pfizer Surges On First Coronavirus Vaccine Test — But Is PFE Stock A Buy?
12:00pm, Monday, 13'th Jul 2020
Pfizer stock is forming a cup-with-handle base as the Street intently watches its coronavirus vaccine efforts with BioNTech. But is the pharmaceutical company's stock a buy right now?
Mylan (MYL) Obtains FDA Approval for Biosimilar of Humira
02:24pm, Friday, 10'th Jul 2020
Mylan's (MYL) biosimilars portfolio gets a boost with the FDA approval of Hulio, a biosimilar of Humira.
MYL INVESTORS: August 25, 2020 Filing Deadline in Class Action – Contact Lieff Cabraser
01:00pm, Friday, 10'th Jul 2020
MYL INVESTORS: August 25, 2020 Filing Deadline in Class Action – Contact Lieff Cabraser
Edited Transcript of MYL earnings conference call or presentation 11-May-20 2:30pm GMT
05:38am, Friday, 10'th Jul 2020
Q1 2020 Mylan NV Earnings Call
SHAREHOLDER ALERT: CEMI MYL GEO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
11:15pm, Thursday, 09'th Jul 2020
NEW YORK, NY / ACCESSWIRE / July 9, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a lo
NEW YORK, July 09, 2020 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mylan N.V. (NASDAQ: MYL) between February 16, 2016 and May.
Viatris Reveals Branding to Reflect New Company's Transformative Strategy
12:30pm, Thursday, 09'th Jul 2020
Mylan N.V. (NASDAQ: MYL) and Upjohn, a division of Pfizer, today unveiled the logo and branding for VIATRIS™, the new company that will be formed by combining Mylan and Upjohn.
Mylan and Fujifilm Kyowa Kirin Biologics Announce U.S. FDA Approval of Hulio® (adalimumab-fkjp)
10:30am, Thursday, 09'th Jul 2020
Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp), a biosimilar to AbbVie's
Covid-19 Research Update: The Stars and the Question Marks
09:50pm, Wednesday, 08'th Jul 2020
While giants like Gilead Sciences and Pfizer are progressing well, many small players have witnessed setbacks in their Covid-19 research Continue reading...
India's Cipla set to undercut rivals with generic remdesivir -sources
12:59pm, Wednesday, 08'th Jul 2020
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of
